The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
Open accessAbstract
Objective: To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19). Design: Multicentre, open label, randomised controlled trial. Setting: 16 government designated covid-19 treatment centres in China, 11 to 29 February 2020. Participants: 150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone). Interventions: Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively). Main outcome measure: Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according to the intention to treat principle. Adverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone. Results: Of 150 patients, 148 had mild to moderate disease and two had severe disease. The mean duration from symptom onset to randomisation was 16.6 (SD 10.5; range 3-41) days. A total of 109 (73%) patients (56 standard of care; 53 standard of care plus hydroxychloroquine) had negative conversion well before 28 days, and the remaining 41 (27%) patients (19 standard of care; 22 standard of care plus hydroxychloroquine) were censored as they did not reach negative conversion of virus. The probability of negative conversion by 28 days in the standard of care plus hydroxychloroquine group was 85.4% (95% confidence interval 73.8% to 93.8%), similar to that in the standard of care group (81.3%, 71.2% to 89.6%). The difference between groups was 4.1% (95% confidence interval –10.3% to 18.5%). In the safety population, adverse events were recorded in 7/80 (9%) hydroxychloroquine non-recipients and in 21/70 (30%) hydroxychloroquine recipients. The most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients. Two hydroxychloroquine recipients reported serious adverse events. Conclusions: Administration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19. Adverse events were higher in hydroxychloroquine recipients than in non-recipients. Trial registration: ChiCTR2000029868.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citationZhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Self-citationWang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Detection of SARS-CoV-2 in Different Types of Clinical Specimens
Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., & Tan, W. (2020) · JAMA · doi:10.1001/jama.2020.3786 · Cited by 5,028
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1091 · Cited by 3,903
Self-citationYao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Analysing controlled trials with baseline and follow up measurements
Vickers, A. J., & Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7321.1123 · Cited by 2,116
Cited by
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
Self-citationImmunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022926 · Cited by 1,265
Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31180-6 · Cited by 1,200
RetractedHydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., Azevedo, L. C. P., Veiga, V. C., Avezum, A., Damiani, L. P., Marcadenti, A., Kawano-Dourado, L., Lisboa, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019014 · Cited by 1,083
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Self-citationCOVID-19-neutralizing antibodies predict disease severity and survival
Garcia-Beltran, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J., Hauser, B. M., Caradonna, T. M., Clayton, K. L., Nitido, A. D., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.015 · Cited by 722
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19
Magagnoli, J., Narendran, S., Pereira, F., Cummings, T. H., Hardin, J. W., Sutton, S. S., & Ambati, J. (2020) · Med · doi:10.1016/j.medj.2020.06.001 · Cited by 656
An Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 599
Arshad, S., Kilgore, P., Chaudhry, Z. S., Jacobsen, G., Wang, D. D., Huitsing, K., Brar, I., Alangaden, G. J., Ramesh, M. S., McKinnon, J. E., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.099 · Cited by 546
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
TUFAN, A., AVANOĞLU GÜLER, A., & MATUCCI-CERINIC, M. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-168 · Cited by 495
Million, M., Lagier, J.-C., Gautret, P., Colson, P., Fournier, P.-E., Amrane, S., Hocquart, M., Mailhe, M., Esteves-Vieira, V., Doudier, B., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101738 · Cited by 469
The first 12 months of COVID-19: a timeline of immunological insights
Carvalho, T., Krammer, F., & Iwasaki, A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00522-1 · Cited by 443
COVID-19: Discovery, diagnostics and drug development
Asselah, T., Durantel, D., Pasmant, E., Lau, G., & Schinazi, R. F. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.031 · Cited by 437
Covid-19 and the cardiovascular system: a comprehensive review
Azevedo, R. B., Botelho, B. G., Hollanda, J. V. G. D., Ferreira, L. V. L., Junqueira de Andrade, L. Z., Oei, S. S. M. L., Mello, T. D. S., & Muxfeldt, E. S. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-020-0387-4 · Cited by 364
COVID-19: breaking down a global health crisis
Mallah, S. I., Ghorab, O. K., Al-Salmi, S., Abdellatif, O. S., Tharmaratnam, T., Iskandar, M. A., Sefen, J. A. N., Sidhu, P., Atallah, B., El-Lababidi, R., et al. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00438-7 · Cited by 363
SARS-CoV-2 and the pandemic of COVID-19
Adil, M. T., Rahman, R., Whitelaw, D., Jain, V., Al-Taan, O., Rashid, F., Munasinghe, A., & Jambulingam, P. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138386 · Cited by 335
Glasziou, P. P., Sanders, S., & Hoffmann, T. (2020) · BMJ · doi:10.1136/bmj.m1847 · Cited by 330
Emerging treatment strategies for COVID-19 infection
Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Korompoki, E., Fotiou, D., Migkou, M., Tzanninis, I.-G., Psaltopoulou, T., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00671-y · Cited by 326
Fiolet, T., Guihur, A., Rebeaud, M. E., Mulot, M., Peiffer-Smadja, N., & Mahamat-Saleh, Y. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.08.022 · Cited by 306
COVID-19 and Solid Organ Transplantation: A Review Article
Azzi, Y., Bartash, R., Scalea, J., Loarte-Campos, P., & Akalin, E. (2021) · Transplantation · doi:10.1097/tp.0000000000003523 · Cited by 301
Axfors, C., Schmitt, A. M., Janiaud, P., van’t Hooft, J., Abd-Elsalam, S., Abdo, E. F., Abella, B. S., Akram, J., Amaravadi, R. K., Angus, D. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22446-z · Cited by 295
Mitjà, O., Corbacho-Monné, M., Ubals, M., Tebé, C., Peñafiel, J., Tobias, A., Ballana, E., Alemany, A., Riera-Martí, N., Pérez, C. A., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1009 · Cited by 290
Pharmaco-Immunomodulatory Therapy in COVID-19
Rizk, J. G., Kalantar-Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020) · Drugs · doi:10.1007/s40265-020-01367-z · Cited by 288
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Drożdżal, S., Rosik, J., Lechowicz, K., Machaj, F., Szostak, B., Przybyciński, J., Lorzadeh, S., Kotfis, K., Ghavami, S., & Łos, M. J. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100794 · Cited by 286
Risk Factors for Mortality in Patients with COVID-19 in New York City
Mikami, T., Miyashita, H., Yamada, T., Harrington, M., Steinberg, D., Dunn, A., & Siau, E. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05983-z · Cited by 284
Trougakos, I. P., Stamatelopoulos, K., Terpos, E., Tsitsilonis, O. E., Aivalioti, E., Paraskevis, D., Kastritis, E., Pavlakis, G. N., & Dimopoulos, M. A. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-020-00703-5 · Cited by 278
COVID-19 in patients with lung cancer
Luo, J., Rizvi, H., Preeshagul, I. R., Egger, J. V., Hoyos, D., Bandlamudi, C., McCarthy, C. G., Falcon, C. J., Schoenfeld, A. J., Arbour, K. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.007 · Cited by 267
Lucien, M. A. B., Canarie, M. F., Kilgore, P. E., Jean-Denis, G., Fénélon, N., Pierre, M., Cerpa, M., Joseph, G. A., Maki, G., Zervos, M. J., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.12.087 · Cited by 256
CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081124 · Cited by 205
Artificial intelligence, drug repurposing and peer review
Levin, J. M., Oprea, T. I., Davidovich, S., Clozel, T., Overington, J. P., Vanhaelen, Q., Cantor, C. R., Bischof, E., & Zhavoronkov, A. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0686-x · Cited by 79
Bero, L., Lawrence, R., Leslie, L., Chiu, K., McDonald, S., Page, M. J., Grundy, Q., Parker, L., Boughton, S., Kirkham, J. J., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-051821 · Cited by 50
Chandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
Wong, A. O.-T., Gurung, B., Wong, W. S., Mak, S. Y., Tse, W. W., Li, C. M., Lieu, D. K., Costa, K. D., Li, R. A., & Hajjar, R. J. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.12.014 · Cited by 16
Metadata
- Authors
- Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., Chen, W., Wang, X., Yang, J., Lin, J., Zhao, Q., Yan, Y., Xie, Z., Li, D., Yang, Y., Liu, L., Qu, J., Ning, G., Shi, G., & Xie, Q.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2020-05-14
- Volume
- 369
- Pages
- m1849
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3025795175
- Cited by
- 1,135
- References
- 22
- FWCI
- 33.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.